Changes of MicroRNA-1, -15b and -21 Levels in Irradiated Rat Hearts After Treatment With Potentially Radioprotective Drugs

Kura, Branislav; Yin, Chang; Frimmel, Karel; Krizak, J.; Okruhlicová, Ľudmila; Kukreja, Rakesh C.; Slezák, J

doi:10.33549/physiolres.933399

Cited by 30 publications

(18 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…unchanged miR-21 in left ventricles in patients with hypertrophic cardiomyopathy [10] ↑miR-21 in fibroblasts of the pressure-overloaded heart [97] unchanged miR-21 in cardiomyocytes of the pressure-overloaded heart [97] Diabetic cardiomyopathy miR-1 ↑miR-1 regulation in H9C2 in high glucose [98] ↓miR-1 in cardiomyocytes treated with high glucose [99] miR-21 ↑miR-21 in high glucose-treated cardiac fibroblasts [100] Viral myocarditis miR-21 ↑miR-21 in human and murine coxsakcie B3 myocarditis [101,102] Radiation-induced heart disease miR-1 ↓miR-1 in left ventricle six weeks after 25 Gy and 10 Gy irradiation of mediastinum area [103,104] miR-21 ↑miR-21 in left ventricle six weeks after 25 Gy and 10 Gy irradiation of mediastinum area [103,104] Anthracyclines-induced cardiomyopathy miR-1…”

Section: Type Of Cvd Mir Findings Referencementioning

confidence: 99%

“…Among the miRs connected with radiation-induced heart disease are also miR-1 and miR-21. Kura et al [103] reported the down-regulation of miR-1 and the up-regulation of miR-21 in the rat myocardium six weeks after single irradiation of the mediastinum area with a total dose of 25 Gy. These results were confirmed in their next study in 2019 when RT-qPCR proved the down-regulation of miR-1 and the up-regulation of miR-21 in rats' left ventricle after 10 Gy of irradiation in the mediastinal area.…”

Section: Role Of Mir-1 and Mir-21 In The Heart Injury Caused By Radiomentioning

confidence: 99%

See 1 more Smart Citation

Potential Clinical Implications of miR-1 and miR-21 in Heart Disease and Cardioprotection

Kura

Kaločayová

Devaux

et al. 2020

IJMS

View full text Add to dashboard Cite

The interest in non-coding RNAs, which started more than a decade ago, has still not weakened. A wealth of experimental and clinical studies has suggested the potential of non-coding RNAs, especially the short-sized microRNAs (miRs), to be used as the new generation of therapeutic targets and biomarkers of cardiovascular disease, an ever-growing public health issue in the modern world. Among the hundreds of miRs characterized so far, microRNA-1 (miR-1) and microRNA-21 (miR-21) have received some attention and have been associated with cardiac injury and cardioprotection. In this review article, we summarize the current knowledge of the function of these two miRs in the heart, their association with cardiac injury, and their potential cardioprotective roles and biomarker value. While this field has already been extensively studied, much remains to be done before research findings can be translated into clinical application for patient’s benefit.

show abstract

Section: Type Of Cvd Mir Findings Referencementioning

confidence: 99%

Section: Role Of Mir-1 and Mir-21 In The Heart Injury Caused By Radiomentioning

confidence: 99%

Potential Clinical Implications of miR-1 and miR-21 in Heart Disease and Cardioprotection

Kura

Kaločayová

Devaux

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…In irradiated rats, miR-1 was found downregulated in the heart [87,139]. miR-1 plays a pivotal role in electrical coupling and direct cardiac cell to cell communication to ensure heart function, since it targets intercellular Cx43 channels [140].…”

Section: Mir-1mentioning

confidence: 99%

MicroRNAs in Cancer Treatment-Induced Cardiotoxicity

Pellegrini

Sileno

D'agostino

et al. 2020

Cancers

View full text Add to dashboard Cite

Cancer treatment has made significant progress in the cure of different types of tumors. Nevertheless, its clinical use is limited by unwanted cardiotoxicity. Aside from the conventional chemotherapy approaches, even the most newly developed, i.e., molecularly targeted therapy and immunotherapy, exhibit a similar frequency and severity of toxicities that range from subclinical ventricular dysfunction to severe cardiomyopathy and, ultimately, congestive heart failure. Specific mechanisms leading to cardiotoxicity still remain to be elucidated. For instance, oxidative stress and DNA damage are considered key players in mediating cardiotoxicity in different treatments. microRNAs (miRNAs) act as key regulators in cell proliferation, cell death, apoptosis, and cell differentiation. Their dysregulation has been associated with adverse cardiac remodeling and toxicity. This review provides an overview of the cardiotoxicity induced by different oncologic treatments and potential miRNAs involved in this effect that could be used as possible therapeutic targets.Cancers 2020, 12, 704 2 of 24 circulating miRNAs have been used as excellent biomarkers in different studies and can be used as biomarkers for cardiovascular diseases (CVDs) [5]. Moreover, miRNA deregulation is often associated with tumor progression, and many anticancer treatments affect miRNA expression. In this review we aimed to discuss relevant miRNAs modulated by therapies for cancer that have been demonstrated to be involved in CVD. In the following paragraphs, we provide an overview of the most important anticancer treatments that are known to induce cardiotoxicity. Anticancer Treatment and CardiotoxicityAnticancer treatment has accomplished remarkable progress in the last century resulting in improved quality of life and survival rates of cancer patients. These advances in cancer treatment, however, have been often accompanied by therapy-related complications, including secondary side effects on the whole organism [6].The most commonly used cancer therapeutics in modern medicine include the traditional surgery, radiotherapy, and conventional chemotherapy approaches; moreover, two new therapeutic modalities have been introduced in recent decades, namely molecularly targeted therapy and immunotherapy [7], as summarized in Figure 1. Traditional chemotherapy agents consist of non-specific cytotoxic treatments (e.g., alkylating agents and antimetabolites) that rapidly eliminate replicating cells, including not only tumor cells but also normal tissue cells, with a broad range of side effects that significantly limit their applications in cancer therapy. In contrast to conventional systemic chemotherapy, molecularly targeted cancer therapies, using novel drugs aimed at the inhibition of intracellular signaling pathways fundamental for cancer proliferation or differentiation (e.g., monoclonal antibodies and low molecular weight protein-kinase inhibitors), are thought to be cancer-specific, with fewer associated adverse effects on normal cells [8]. Lastly, immunother...

show abstract

“…The expression of some miRNAs is highly tissue-specific, e.g. miR-1 and -133 (cardiac and skeletal muscle), miR-122 (liver), and miR-124a (brain) (Lagos-Quintana et al 2002). Among others, kidney-specific miRNAs (miR-192, -194, -204, and -215) Of the cardiac-specific miRNAs, miR-1 acts as a regulator of differentiation and proliferation during cardiogenesis and as a regulator of cardiomyocyte growth in the adult heart.…”

Section: Intracellular Mirnasmentioning

confidence: 99%

“…Of the possible epigenetic mechanisms that lead to disease development, in addition to DNA methylation (almost exclusively cytosine methylation within the sequences with a high proportion of CG repeats) and histone modification (methylation, acetylation, phosphorylation, ubiquitination) more and more attention is now being focused on the analysis of regulatory RNA molecules (Udali et al 2013, Kuneš et al 2015, Kura et al 2016.…”

Section: Introductionmentioning

confidence: 99%

Regulatory RNAs and Cardiovascular Disease – With a Special Focus on Circulating MicroRNAs

Dlouhá

Hubacek²

2017

Physiol Res

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are a class of short non-coding regulatory RNA molecules which play an important role in intracellular communication and cell signaling and which influence cellular processes such as proliferation, differentiation, and cellular death. Over the past two decades, the crucial role of microRNAs in controlling tissue homeostasis and disease in cardiovascular systems has become widely recognized. By controlling the expression levels of their targets, several miRNAs have been shown to modulate the function of endothelial cells (miR-221/222 and -126), vascular smooth muscle cells (miR-143/145) and macrophages (miR-33, -758, and -26), thereby regulating the development and progression of atherosclerosis. The stability of miRNAs within the blood suggests that circulating miRNAs may function as important biomarkers of disease development and progression. Numerous circulating miRNAs have been found to be dysregulated in a wide variety of different disease states, including diabetes, cancer, and cardiovascular disease.

show abstract

Changes of MicroRNA-1, -15b and -21 Levels in Irradiated Rat Hearts After Treatment With Potentially Radioprotective Drugs

Cited by 30 publications

References 43 publications

Potential Clinical Implications of miR-1 and miR-21 in Heart Disease and Cardioprotection

Potential Clinical Implications of miR-1 and miR-21 in Heart Disease and Cardioprotection

MicroRNAs in Cancer Treatment-Induced Cardiotoxicity

Regulatory RNAs and Cardiovascular Disease – With a Special Focus on Circulating MicroRNAs

Contact Info

Product

Resources

About